



## PEOPLE

**Alan P. Wolffe**, senior vice president and chief scientific officer at Sangamo BioSciences (Richmond, CA), has died. He was attending an international scientific meeting and was involved in a fatal traffic accident. Internationally recognized for his research on chromatin structure and its role in the regulation of gene expression, Dr. Wolffe was director of the Department of Molecular Embryology at the National Institutes of Child Health and Human Development until March 2000, when he joined Sangamo.

**Adrian Adams**, most recently president and CEO of Novartis Pharmaceuticals UK, has joined Kos Pharmaceuticals (Miami, FL) as president and chief operating officer. Also, **Daniel M. Bell**, a co-founder and current president and CEO of Kos, has become chairman of the board of directors and **Michael Jaharis**, co-founder and chairman, has become chairman emeritus.

Isis Pharmaceuticals (Carlsbad, CA) has announced the appointment of **Richard K. Brown** as president of the company's functional genomics division, GeneTrove, and as vice president of Isis. Dr. Brown was previously president of Irori, the technology and instrumentation division of Discovery Partners International.

British Biotech (Oxford, UK) Director of Business Development **Tim Edwards** has been promoted to chief business officer. Mr. Edwards will also continue to serve as an executive director of the company.

ArQule (Woburn, MA) has announced the appointment of **Ariel Elia** to the role of non-executive chairman of the board of directors. He joined the board in October 2000, after an almost 30-year career at Merck & Co. and American Home Products. Mr. Elia takes over the chairman's role, which has been vacant since the retirement of Joseph C. Hogan Jr. in November 1999. Additionally, **Michael Rivard** has been named to the newly created position of vice president, strategic development. Mr. Rivard joined ArQule in 1997 and has held the position of vice president, legal and general counsel.

**William Goeckeler** has been promoted to vice president, R&D at Cytogen (Princeton, NJ), a newly created position. He joined Cytogen in March of 1994, and has served as director of pharmaceutical development since 1997.

Human Genome Sciences (Rockville, MD) has announced that **Richard C. Holbrooke**, former US ambassador to the United Nations, and **Richard J. Danzig**, former US

secretary of the Navy, have been appointed to the company's board of directors. Mr. Holbrooke is a board member of AIG and the National Endowment for Democracy, chairman of International Rescue Committee and Refugees International, and vice chairman of Perseus LLC. Mr. Danzig is a director of National Semiconductor Corp. Human Genome Sciences has also announced the resignation of **Beverly Sills Greenough** from its board. Mrs. Sills Greenough, who had been a director of Human Genome Sciences since 1994, is chairman of Lincoln Center for the Performing Arts. The resignation of Mrs. Sills Greenough and the appointment of Messrs. Holbrooke and Danzig bring the board's membership to 10 members.

Beyond Genomics (Waltham, MA) has named **Eric Neumann** vice president of bioinformatics. He joins the company from 3rd Millennium, where he was vice president of life science informatics. He is founder and organizer of the international BioPathways Consortium and is an advisory member of Sun Microsystems' Life Sciences Open-Platform Initiative (I3C).

NeoRx (Seattle, WA) has appointed **Wolfgang Oster** chief operating officer. Dr. Oster joins the company from US Bioscience, which recently merged with MedImmune. At US Bioscience, he served as executive vice president of worldwide clinical research.

**Wayne Schnarr** has been appointed vice president, corporate development at Oncolytics Biotech (Calgary, AB, Canada). Dr. Schnarr was most recently the biotechnology analyst with Canaccord Capital Corp., and was previously a vice president and a director of BioCatalyst Yorkton, a venture management firm.



Calyx Therapeutics (Hayward, CA) has named **Mark W. Schwartz** president and CEO. He will also join the board of directors. Dr. Schwartz joins the company from Trega BioSciences/Lion Bioscience, where he previously served as chief commercial officer.

**Michael Young** has been appointed vice president of business development at deCODE Genetics (Reykjavik, Iceland), a new position. For the past six years, he has served as vice president of commercial development at Genzyme Transgenics.